Thrombospondin‐1‐induced vascular smooth muscle cell chemotaxis: The role of the type 3 repeat and carboxyl terminal domains

Thrombospondin‐1 (TSP‐1), an acute phase reactant implicated in vascular disease, is a matricellular glycoprotein with six domains that confer different functions. The authors have shown TSP‐1 induces vascular smooth muscle cell (VSMC) chemotaxis via extracellular signal‐regulated kinases‐1 and ‐2 (ERK) and p38 kinase (p38) and that a fusion protein of the carboxyl terminal (COOH) and type 3 repeat (T3) domains independently induce VSMC chemotaxis. The purpose of this study was to determine whether COOH‐, T3‐induced VSMC chemotaxis, or both, is dependent upon ERK or p38 activation. To determine if the T3, COOH, or type 2 repeat domain (T2, control domain not associated with chemotaxis) activate ERK, p38, or both, VSMCs were exposed to each fusion protein (20 μg/ml for 15, 30, 60, or 120 min), serum‐free media (SFM, negative control), or TSP‐1 (20 μg/ml for 30 min, positive control). Western immunoblotting was performed for activation studies. Using a microchemotaxis chamber, VSMCs pre‐incubated in SFM, DMSO (vehicle control), PD98059 (10 μM), or SB202190 (10 μM) were exposed to each domain, TSP‐1, or SFM. After 4 h (37°C), migrated VSMCs were recorded as cells/five fields (400 ×) and analyzed by paired t‐test. ERK was activated by T2, T3, and COOH. However, p38 was activated by T3 and COOH, but not T2. T3 and COOH‐induced VSMC chemotaxis were inhibited by PD98059 or SB202190, but more completely by SB202190. The T2 domain had no effect on VSMC chemotaxis. These results suggest activation of the p38 pathway may be more specific than ERK for COOH‐ and T3‐induced VSMC chemotaxis. © 2003 Wiley‐Liss, Inc.

[1]  V. Gahtan,et al.  The C-terminal domain of thrombospondin-1 induces vascular smooth muscle cell chemotaxis. , 2001, Journal of vascular surgery.

[2]  E. Vellenga,et al.  The p38 MAP kinase inhibitor SB203580 enhances nuclear factor‐kappa B transcriptional activity by a non‐specific effect upon the ERK pathway , 2000, British journal of pharmacology.

[3]  V. Gahtan,et al.  Inhibition of phosphatidylinositol 3-kinase and protein kinase C attenuates extracellular matrix protein-induced vascular smooth muscle cell chemotaxis. , 2000, Journal of vascular surgery.

[4]  J. Hedges,et al.  A Role for p38MAPK/HSP27 Pathway in Smooth Muscle Cell Migration* , 1999, The Journal of Biological Chemistry.

[5]  V. Gahtan,et al.  Thrombospondin-1 regulation of smooth muscle cell chemotaxis is extracellular signal-regulated protein kinases 1/2 dependent. , 1999, Surgery.

[6]  G. Kapoor,et al.  One-way cross-talk between p38(MAPK) and p42/44(MAPK). Inhibition of p38(MAPK) induces low density lipoprotein receptor expression through activation of the p42/44(MAPK) cascade. , 1999, The Journal of biological chemistry.

[7]  G. Kapoor,et al.  One-way Cross-talk between p38MAPK and p42/44MAPK , 1999, The Journal of Biological Chemistry.

[8]  H. Krutzsch,et al.  Differential roles of protein kinase C and pertussis toxin-sensitive G-binding proteins in modulation of melanoma cell proliferation and motility by thrombospondin 1. , 1998, Cancer research.

[9]  Xue-qing Wang,et al.  The Thrombospondin Receptor CD47 (IAP) Modulates and Associates with α2β1 Integrin in Vascular Smooth Muscle Cells , 1998 .

[10]  N. Tonks,et al.  Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. , 1997, Science.

[11]  A. Hughes,et al.  Thrombospondin-1 is a potent mitogen and chemoattractant for human vascular smooth muscle cells. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[12]  G. Tuszynski,et al.  Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells. , 1997, Experimental cell research.

[13]  J C Lee,et al.  Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. , 1997, Biochemical and biophysical research communications.

[14]  J. Chung,et al.  Thrombspondin Acts via Integrin-associated Protein to Activate the Platelet Integrin αIIbβ3 * , 1997, The Journal of Biological Chemistry.

[15]  David A. Cheresh,et al.  Regulation of Cell Motility by Mitogen-activated Protein Kinase , 1997, The Journal of cell biology.

[16]  M. Cobb,et al.  Mitogen-activated protein kinase pathways. , 1997, Current opinion in cell biology.

[17]  E. Brown,et al.  Thrombospondin modulates alpha v beta 3 function through integrin- associated protein , 1996, The Journal of cell biology.

[18]  K. Yamada,et al.  Cell attachment. , 1995, Advances in dental research.

[19]  M. Reed,et al.  Expression of thrombospondins by endothelial cells. Injury is correlated with TSP-1. , 1995, The American journal of pathology.

[20]  A. Bridges,et al.  A synthetic inhibitor of the mitogen-activated protein kinase cascade. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Bornstein,et al.  Diversity of Function Is Inherent in Matricellular Proteins: an Appraisal of Thrombospondin I , 1995 .

[22]  P. Hogg Thrombospondin 1 as an Enzyme Inhibitor , 1994, Thrombosis and Haemostasis.

[23]  J. Lawler,et al.  Cell-type specific adhesive interactions of skeletal myoblasts with thrombospondin-1. , 1994, Molecular biology of the cell.

[24]  M. Höök,et al.  Heparin-binding peptides from thrombospondins 1 and 2 contain focal adhesion-labilizing activity. , 1993, The Journal of biological chemistry.

[25]  U. Ryan,et al.  Thrombospondin mediates migration and potentiates platelet‐derived growth factor‐dependent migration of calf pulmonary artery smooth muscle cells , 1993, Journal of cellular physiology.

[26]  J. Miano,et al.  Smooth muscle cell immediate-early gene and growth factor activation follows vascular injury. A putative in vivo mechanism for autocrine growth. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[27]  C. Legrand,et al.  Molecular requirements for the interaction of thrombospondin with thrombin-activated human platelets: modulation of platelet aggregation. , 1992, Blood.

[28]  R. Nachman,et al.  Cellular attachment to thrombospondin. Cooperative interactions between receptor systems. , 1991, The Journal of biological chemistry.

[29]  R. Hynes,et al.  Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors , 1988, The Journal of cell biology.

[30]  L. Liotta,et al.  Thrombospondin-induced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domains , 1987, The Journal of cell biology.

[31]  D. Roberts,et al.  Platelet thrombospondin mediates attachment and spreading of human melanoma cells , 1987, The Journal of cell biology.

[32]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Hedges,et al.  A Role for p 38 MAPK / HSP 27 Pathway in Smooth Muscle Cell Migration , 1999 .

[34]  V. Swami,et al.  Thrombospondin-1 is elevated with both intimal hyperplasia and hypercholesterolemia. , 1998, The Journal of surgical research.

[35]  X. Wang,et al.  The thrombospondin receptor CD47 (IAP) modulates and associates with alpha2 beta1 integrin in vascular smooth muscle cells. , 1998, Molecular biology of the cell.

[36]  E. Fleck,et al.  Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. , 1997, Hypertension.